Skip to main content
IMNM
NASDAQ Life Sciences

Immunome CEO Buys Over $500K in Open Market Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$19.096
Mkt Cap
$2.183B
52W Low
$5.15
52W High
$27.65
52W Position info
271% above low
Off High info
31% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

IMNM has more than doubled off its 52-week low of $5.15.

Summary

Immunome Inc.'s CEO, Clay B. Siegall, purchased over $500,000 of company stock in an open market transaction, signaling strong executive confidence.


Key Events · Ownership and Investor Activity · IMNM

  • CEO Open Market Purchase

    Clay B. Siegall, President and CEO, acquired 25,450 shares of Immunome Inc. common stock for a total value of $500,601.50 on March 27, 2026.

  • Executive Confidence Signal

    This substantial direct investment by the company's top executive, made at an average price of $19.67 per share (above the current stock price of $19.096), signals strong belief in the company's valuation and future outlook.

  • Increased Direct Holdings

    Following this transaction, the CEO's direct holdings increased to 690,704 shares.


Analysis · IMNM · Life Sciences

Immunome Inc.'s President and CEO, Clay B. Siegall, demonstrated strong conviction by acquiring 25,450 shares of company stock in an open market purchase totaling over $500,000. This significant investment, made at an average price of $19.67 per share (slightly above the current stock price of $19.096), signals the top executive's belief in the company's future prospects and potential undervaluation. Such direct insider buying often aligns management's interests with shareholders and can be interpreted as a positive indicator for investors.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMNM was trading at $19.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.15 to $27.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMNM - Latest Insights

IMNM
Sep 30, 2026, 7:45 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $21.72
Real-time Price: $21.86 info
Change: +$0.140 (+0.64%) info
Market Cap: $2.443B info
IMNM
Aug 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $26.25
Real-time Price: $21.86 info
Change: -$4.39 (-17%) info
Market Cap: $2.443B info
IMNM
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.25
Real-time Price: $21.86 info
Change: -$4.39 (-17%) info
Market Cap: $2.443B info
IMNM
Aug 11, 2026, 4:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.25
Real-time Price: $21.86 info
Change: -$4.39 (-17%) info
Market Cap: $2.443B info
IMNM
Jul 20, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $21.80
Real-time Price: $21.86 info
Change: +$0.060 (+0.28%) info
Market Cap: $2.443B info